News

The therapy, known as Prostvac-vf, is designed to stimulate the patient’s own immune system to seek out and destroy malignant cells expressing prostate-specific antigen (PSA), a substance often

The definitive merger agreement was unanimously approved by the directors of both companies. Omnicare agreed to pay $1.55 billion to secure the deal that will result in the

Based on research showing that Ceragenix’s drugs have activity similar to human angiostatins, two of the company’s lead cationic steroid antibiotic (CSA) compounds have been accepted by the

The compound, PTC124, has been granted orphan drug status by the Committee for Orphan Medicinal Products, a unit of the European Medicines Agency (EMEA). Such status is granted

Human Genome is developing LymphoStat-B as a potential treatment for rheumatoid arthritis and systemic lupus erythematosus, already establishing the drug’s safety and efficacy during initial clinical trials. LymphoStat-B

Under the terms of the agreement, Napo has granted development and commercialization rights to Glenmark in their territories for pediatric diarrhea, acute infectious diarrhea and AIDS-related diarrhea. Glenmark

The issued patent covers a novel class of potent apoptosis inducers with vascular targeting activity that inhibit microtubule formation. The lead compound in this series is MX2407, which

The pivotal trial is a placebo-controlled morbidity and mortality study with over 2,000 patients, designed to assess time to doubling of serum creatinine, end-stage renal disease or death

Schering-Plough is planning to use ViroLogic’s HIV resistance testing technology in the development of its CCR5 receptor antagonist, vicriviroc. CCR5 receptor antagonists are a type of HIV Entry